Company: BDRX
Filing Date: 2025-11-17
Form Type: POS AM
Source: 0001214659-25-016809
Chunk: 45

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-11-17
Form: POS AM
Chunk 45
---
 cash or substantially all
cash transaction, (ii) a “Rule 13e-3 transaction” as defined in Rule 13e-3 under the Exchange Act, or (iii) with certain
limited exceptions, a fundamental transaction involving a person or entity not traded on a national securities exchange or other established
trading market, including, but not limited to, the London Stock Exchange, AIM, The New York Stock Exchange, Inc., The NYSE MKT, The NASDAQ
Global Select Market, The NASDAQ Global Market, The NASDAQ Capital Market, the OTC QX, the OTC QB or the Over-the-Counter Bulletin Board,
then the Company or any successor entity will pay at the holder’s option, exercisable at any time concurrently with or within 30
days after the consummation of the fundamental transaction, an amount of cash equal to the value of the warrant as determined in accordance
with the Black Scholes option pricing model.

Transferability. Each warrant
and all rights thereunder are transferable, in whole or in part, upon surrender of the warrant, together with a written assignment of
the warrant subject to applicable securities laws; provided, however, that the Warrant Agent Warrants are subject to certain FINRA transfer
restrictions. We do not intend to apply for listing of the warrants on any securities exchange or other trading system.

No Rights as Shareholder Until Exercise.Except as set forth in the warrants, the holders of the warrants do not have any voting rights, dividends or other rights as a holder of our capital stock until they exercise the warrants.

Series J Warrants and July 2024 Placement Agent Warrants

The following is a brief summary of the Series J Warrants and July 2024 Placement Agent Warrants issued in connection with a July 2024 private placement, and is subject in all respects to the provisions contained in the applicable warrants,which are filed as exhibits
to our Report on Form 6-K dated July 19, 2024. Unless otherwise stated, references to “warrants” in this subsection include the Series J Warrants and July 2024 Placement Agent Warrants.

Exercisability. The warrants
became exercisable on July 22, 2024. The Series J Warrants and July 2024 Placement Agent Warrants expire
five years and three years, respectively from the initial exercise date. The holder shall deliver the aggregate exercise price for the
Depositary Shares specified in the exercise notice within two